Suppr超能文献

结直肠癌细胞减灭术联合腹腔热灌注化疗治疗结直肠肿瘤腹膜转移:韩国单中心长期随访结果

Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastasis of colorectal cancer: long-term follow-up results at a single institution in Korea.

机构信息

Department of Surgery, Dankook University Hospital College of Medicine, 201 Manghyangro, Dongnam-Gu, Cheonan, 31116, Republic of Korea.

出版信息

Int J Colorectal Dis. 2023 Feb 16;38(1):44. doi: 10.1007/s00384-023-04340-w.

Abstract

PURPOSE

This study aimed to examine the 7-year follow-up results of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) for peritoneal metastasis (PM) of colorectal cancer.

METHODS

We performed 54 cases of CRS and IPC in 53 patients with PM of colorectal cancer from December 2011 to December 2013. We prospectively collected data and analyzed peritoneal carcinomatosis grade, completeness of cytoreduction, and long-term follow-up (median, 10 [range, 2-92] months) results.

RESULTS

The mean peritoneal cancer index was 15 (1 ~ 35), and complete cytoreduction was possible in 35 (64.8%) patients. Excluding the four patients who died, 11 (22.4%) out of the 49 patients were alive at the time of the last follow-up, and the overall median survival period was 10.3 months. The overall 2- and 5-year survival rates were 31% and 17%, respectively. Patients with complete cytoreduction had a median survival period of 22.6 months, which was significantly longer than that for patients without complete cytoreduction (3.5 months) (P < 0.001). The 5-year survival rate for patients with complete cytoreduction was 24%, and four patients were still alive without disease.

CONCLUSIONS

CRS and IPC show a 5-year survival rate of 17% in patients with PM of colorectal cancer. A possibility of long-term survival is observed in a selected group. Multidisciplinary team evaluation for careful patient selection and CRS training program to achieve complete cytoreduction are significantly important factors in improving survival rate.

摘要

目的

本研究旨在探讨结直肠癌细胞减灭术(CRS)联合腹腔热灌注化疗(IPC)治疗结直肠腹膜转移(PM)的 7 年随访结果。

方法

我们对 2011 年 12 月至 2013 年 12 月期间收治的 53 例结直肠 PM 患者实施了 54 例 CRS 和 IPC。我们前瞻性地收集了数据,并对腹膜癌细胞转移分级、细胞减灭术的完整性以及长期随访(中位数为 10 [范围为 2~92] 个月)结果进行了分析。

结果

腹膜癌指数平均为 15(1~35),35 例(64.8%)患者可达到完全细胞减灭术。在排除 4 例死亡患者后,49 例患者中有 11 例(22.4%)在最后一次随访时仍存活,总中位生存时间为 10.3 个月。总的 2 年和 5 年生存率分别为 31%和 17%。完全细胞减灭术患者的中位生存时间为 22.6 个月,明显长于未达到完全细胞减灭术患者的 3.5 个月(P<0.001)。完全细胞减灭术患者的 5 年生存率为 24%,有 4 例患者仍无病生存。

结论

CRS 和 IPC 治疗结直肠 PM 患者的 5 年生存率为 17%。在选择的患者中,观察到长期生存的可能性。多学科团队评估、仔细的患者选择以及实现完全细胞减灭术的 CRS 培训计划是提高生存率的重要因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验